DVRd Improves MRD Negativity, Maintains Quality of Life in Multiple Myeloma
June 12th 2025Two posters presented at the 2025 European Hematology Association Congress support combination therapy with daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) in transplant-ineligible or deferred newly diagnosed multiple myeloma.
Read More
Rusfertide Offers Sustainable PV Management Strategy: Andrew Kuykendall, MD
June 11th 2025Andrew Kuykendall, MD, Moffitt Cancer Center, explains the goals of the VERIFY trial and why its data on rusfertide could have paradigm-changing implications for patients with polycythemia vera (PV) who currently rely on frequent phlebotomies for relief.
Watch
Blister Packs May Help Solve Medication Adherence Challenges and Lower Health Care Costs
June 10th 2025Julia Lucaci, PharmD, MS, of Becton, Dickinson and Company, discusses the benefits of blister packaging for chronic medications, advocating for payer incentives to boost medication adherence and improve health outcomes.
Listen
Retifanlimab Approval Sets New Standard of Care in Advanced Anal Cancer: Sheela Rao, MBBS, MD, FRCP
June 9th 2025With the FDA approval of retifanlimab (Zynyz; Incyte) as the first and only first-line treatment for advanced anal cancer, researchers are now focusing on resistance mechanisms and future therapies, according to Sheela Rao, MBBS, MD, FRCP, of The Royal Marsden Hospital.
Watch